This trial will assess the long-term efficacy, immunogenicity, and safety of the herpes zoster subunit vaccine in older adults.
0 Primary · 6 Secondary · Reporting Duration: From 1-month post-Dose 2 in the ZOSTER-006/022 studies until the end of the ZOSTER-101 study at Month 48
3662 Total Participants · 0 Treatment Group
Primary Treatment: Treatment · No Placebo Group · Phase 3
Age 18+ · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: